After trying many approaches, complement inhibition was viewed as being the best way to modulate the activity of macrophages in the back of the eye. The role of macrophages in the chronic inflammatory disease process is well understood and has been shown to be a factor in dry Macular Degeneration. The role of complement in macular degeneration was established in 2005 as the first breakthrough discovery resulting directly (Read more...)
Dr. Cedric Francois Discusses the Complement C3 Inhibitor POT-4 for AMD
Cedric Francois MD, PhD, President/CEO of Potentia Pharmaceuticals describes his company's novel anti-AMD compound (POT-4) in a conversation with Dr. Sophie Bakri.